Skip to main
ALXO
ALXO logo

ALXO Stock Forecast & Price Target

ALXO Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

ALX Oncology Holdings Inc is advancing its clinical-stage immuno-oncology pipeline with promising candidates such as the CD47 blocker, evorpacept, currently undergoing phase 1 and 2 clinical trials, alongside the recently added EGFR-targeting ADC, ALX2004, which is designed to enhance safety and efficacy. The company has reported promising metrics, including a median progression-free survival (mPFS) of approximately 7 months in its TRP control group, outperforming industry benchmarks and indicating the potential for durable patient responses. Additionally, combination studies involving evorpacept with anti-HER2 antibodies have shown strong efficacy, particularly in HER2-positive breast cancer, reinforcing the company’s optimistic developmental outlook.

Bears say

ALX Oncology Holdings Inc. has experienced a downward revision in its peak penetration rate estimate for Head and Neck cancer, decreased from 25% to 10%, reflecting concerns over the competitive landscape in oncology treatments. The company reported no revenues for 4Q24 and a net loss per share of $0.55, which, while slightly better than consensus estimates, indicates ongoing financial struggles amidst heightened uncertainty regarding its clinical trial outcomes and the potential for FDA rejection. Furthermore, the anticipated data from interim phase 2 results for breast and colorectal cancer (CRC) will not be available until 2026, contributing to a lack of confidence in the company's near-term growth prospects and financial stability.

ALXO has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ALX Onconology Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ALX Onconology Holdings Inc (ALXO) Forecast

Analysts have given ALXO a Buy based on their latest research and market trends.

According to 7 analysts, ALXO has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ALX Onconology Holdings Inc (ALXO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.